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Summary: Cilofungin was combined with 
amphotericin B or flucytosine to deter- 
mine if synergistic inhibition or killing oc- 
curred against 50 strains of various Can- 
dida species. Synergistic inhibition of 
growth occurred only once with ampho- 
tericin B and cilofungin and only 2 times 
with flucytosine and cilofungin. Synergis- 
tic killing occurred in 5 strains with the 
amphotericin B-cilofungin combination 
and in 7 strains with the flucytosine-cilo- 
fungin combination. Antagonism occurred 
frequently with both the amphotericin 
B-cilofungin and the flucytosine-cilofungin 
combinations. 
Zusammenfassung: Cilofungin wurde mit 
Amphotericin B oder Flucytosin kombi- 
niert, um eine etwaige synergistische 
Wachstumshemmung oder Inaktivierung 
von 50 Stammen unterschiedlicher Candi- 
da-Arten zu untersuchen. Eine synergisti- 
sche Wachstumshemmung wurde nur ein- 
ma1 mit Amphotericin B und Cilofungin 
und zweimal rnit Flucytosin und Cilofungin 
beobachtet. Eine synergistische Abtotung 
trat an 5 Stammen mit der Amphotericin 
B-Cilofungin- und an 7 Stammen mit der 
Flucytosin-Cilofungin-Kombination auf. 
Haufiger wurden bei beiden Kombinatio- 
nen Antagonismen gefunden. 
Introduction 
LY 121019, now known as cilofungin, is a 
new antifungal agent which has been 
shown to be effective against several Can- 
dida species, especially Candida albicans 
and C. tropicalis, the major causes of dis- 
seminated candidosis (2-4, 7, 8). It has 
been suggested that the drug may be effec- 
tive against C. krusei and C. glabrata al- 
though the minimum inhibitory concentra- 
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tion (MIC) is generally higher for these or- 
ganisms (2, 7). Against other Candida 
strains and other yeast-like fungi cilofungin 
does not appear to be as active (2). 
Currently, the drug of choice for serious 
Candida infections is arnphotericin B, des- 
pite its serious toxicity (6). In some instan- 
ces, flucytosine can be added to synergisti- 
cally treat Candida infections (5). Combi- 
nation therapy with flucytosine and am- 
photericin B has the added advantage of 
allowing reduction of the daily ampho- 
tericin B dose and thus decreasing the tox- 
icity (1). We tested cilofungin with ampho- 
tericin B and with flucytosine in vitro to 
determine if synergism might occur when 
this new anti-Candida drug was combined 
with the drugs used commonly in the treat- 
ment of candidosis. 
Materials and Methods 
Fungi 
Fifty clinical isolates of Candida species 
maintained in our laboratory were exam- 
ined. Organisms grown overnight on Sab- 
ouraud dextrose agar (Difco, Inc., Detroit, 
MI) were suspended in 0.9% saline to a 
concentration of 2 x lo7 CFU/ml, (0.55 
optical density reading at 660 nm). The 
final inoculum was prepared in either Sab- 
ouraud dextrose broth (Difco, Inc.), or 
yeast nitrogen base broth (YNB) (Difco, 
Inc.), depending on which drug was to be 
studied. 
Antifungal agents 
Cilofungin (Lilly Research Laboratories, 
Indianapolis, IN) was solubilized in 50% 
ethanol to give a concentration of 1000 
pg/ml. A further dilution was made in 
either Sabouraud dextrose broth or YNB 
to give a concentration of 80 pg/ml. 
Amphotericin B (Fungizone) (E.R. 
Squibb & Sons, Inc., Princeton, NJ) was so- 
lubilized in sterile distilled water to a con- 
centration of 1000 pg/ml and further 
diluted in Sabouraud dextrose broth to a 
concentration of 20 pg/ml. 
Flucytosine (Hoffman-LaRoche Inc., 
Nutley, NJ) was solubilized in sterile 0.9 Oh 
saline to give a concentration of 1000 
pg/ml and further diluted in YNB broth to 
a concentration of 20 pg/ml. 
Susceptibility determinations 
Initial studies were performed to deter- 
mine the MIC each of the 50 isolates for ci- 
lofungin, amphotericin B, and flucytosine. 
Sabouraud dextrose broth was used for 
amphotericin B MICs; Y N B  was used for 
flucytosine MICs. MICs for cilofungin 
were determined for both media. Initially, 
100 p1 of the broth was added to each well 
except the first of a 96 well U bottom 
microtiter plate (Flow Laboratories, Inc., 
McLean, VA). For cilofungin, 100 p1 of the 
80 pg/ml solution was added to the first 
well of each row, and for amphotericin B 
and flucytosine, 100 pl of the 20 pg/ml sol- 
ution was added to the first well of each 
row. Serial twofold dilutions were made 
across the plate using a Costar octapette 
(Costar, Inc., Cambridge, MA). The final 
well received no drug, serving as a positive 
growth control. The concentration of cilo- 
fungin ranged from 0.04 pg/ml to 40 
pg/ml, while that of arnphotericin B and 
flucytosine ranged from 0.01 pg/ml to 10 
pg/ml. Each different fungal isolate was 
added to the 12 wells in a given row so that 
the final inoculum was 1 x lo3 CFU/well. 
Plates were incubated for 24 h at 30°C. The 
MIC was determined as the lowest concen- 
tration showing no visible turbidity using a 
microtiter plate reader. 
After determining the MIC for each 
drug for each of the 50 organisms, synergy 
studies were performed in a similar manner 
by determining the MIC for each drug in 
the presence of a constant amount of the 
other drug added at a concentration four- 
fold less than the previously determined 
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Table 1: Comparison of MIC of cilofungin (CF) alone or with amphotericin B (AmB) or flucytosine 
( 5  FC) against 50 strains of Cundidu 
Cumulative percentage of strains inhibited a t  indicated concentration (pg/ml) 
.04 .08 .16 .31 .62 1.25 2.50 5 10 20 40 
Organism 
C albicans (20) 
CF +AmB 
25 55 100 
20 95 100 
10 95 100 
35 100 






25 37 62 75 87 100 
12 37 62 87 100 
25 62 75 87 100 
25 62 87 100 
C. glabrata (8) 
CF 







C. parapsilosis (8) 
CF 
CF + AmB 
CF 
CF+SFC 
12 50 75 100 
12 50 100 
12 50 100 
50 100 





17 50 67 83 100 
17 33 50 67 83 100 
17 33 67 83 100 
33 50 83 100 
I * C krusei (2), C. pseudotropicalis (2), C. guilliermondii (1 ), C lusitaniae (1) 
MIC. The MIC was read in the same man- 
ner as described above. 
After reading the MIC for each isolate, 
100 pl was taken from those wells which 
showed no turbidity and plated on Sabou- 
raud dextrose agar for assays involving am- 
photericin B and on YNB agar for those in- 
volving flucytosine. The plates were incu- 
bated at 30°C for 24 hrs and the minimum 
fungicidal concentration (MFC) was read 
as the lowest concentration of drug in 
which only one or no fungal colonies per- 
sisted. 
Synergy was defined as a four-fold or 
greater reduction in the MIC or the MFC 
for the combination as compared with the 
value for each drug alone. Antagonism was 
defined as a four-fold or greater increase in 
the MIC or MFC for the combination as 
compared with the value for each drug 
alone. 
Results 
Table 1 shows MICs for cilofungin alone 
and when combined with either ampho- 
tericin B or flucytosine. In no case was the 
addition of amphotericin B to cilofungin 
synergistic; in only one isolate (C. tropi- 
calk) did the addition of flucytosine to cilo- 
fungin produce synergistic inhibition of 
growth. 
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rable 2: Comparison of MIC of amphotericin B (AmB) and flucytosine (5FC) alone or with cilofungin 
[CF) against 50 strains of Cundidu 
Cumulative percentage of strains inhibited at indicated concentration (pg/ml) 
.01 .02 .04 .08 . I6  .31 .62 1.25 2.50 5 10 
3rganism 
C. albicans (20) 
4mB 50 100 
AmB + CF 5 50 70 100 
5 FC 5 10 30 60 
5FC+CF 10 25 50 60 
100 
100 
C. tropicalis (8) 
AmB 50 87 100 
AmB + CF 50 75 87 100 
5 FC 1 2  62 75 100 
5 F C + C F  12 50 62 75 100 
C. alabrata (8) , ,  AGB 25 87 100 
AmB + CF 25 37 50 100 
5 FC 50 62 75 
5 F C + C F  12 37 62 75 100 
100 
C. parapsilosis (8) 
AmB 37 75 100 
AmB + CF 50 100 
5 FC 25 50 62 87 
5FC+CF 12 25 50 75 87 
100 
100 
Candida species (6)* 
Am B 17 83 100 
AmB + CF 33 100 
5 FC 17 50 67 83 100 
5FC+CF 33 67 100 
* C. krusei (2), C. pseudotropicalis (2), C. guilfiermondii (I), C. Iusitaniae (1) 
Antagonism was also uncommon, oc- 
curring only once when flucytosine was 
added to cilofungin. 
Table 2 shows MICs for amphotericin B 
and flucytosine when used singly and when 
combined with cilofungin. Addition of ci- 
lofungin to amphotericin B was synergistic 
once (C. glabrata) and antagonistic in 5 
strains (2 C. tropicalis isolates, and one 
each of C. glabrata, C. albicans, and C. 
parapsilosis). When cilofungin was added 
to flucytosine, synergism occurred only 
once (C. albicans) and antagonism oc- 
curred 8 times (3 C. albicans strains, 2 C, 
glabrata, one each of C. tropicalis, C. guil- 
liermondii, and C. lusitaniae). 
In every instance except one, antago- 
nism and synergism were only four-fold 
higher or lower than the MIC for the single 
drug. In that one instance, a strain of C. gla- 
brata had a MIC for the combination of flu- 
cytosine-cilofungin 8-fold greater than that 
for flucytosine alone. 
Table 3 shows MFCs for cilofungin 
alone and when combined with either am- 
photericin B or flucytosine. No synergism 
with cilofungin-amphotericin B was noted, 
and in only 3 instances (C. tropicalis) was 
synergism seen with the cilofungin-flucyto- 
sine combination. Antagonism, on the 
other hand, was seen more frequently. 
The addition of amphotericin B to cilo- 
fungin increased the MFC 2 4-fold in 2 C. 
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Table 3: Comparison of MFC of cilofungin (CF) alone or with amphotericin B (AmB) or flucytosine 
(5FC) against 50 strains of Cundidu 
Cumulative percentage of strains a t  indicated concentration (pg/ml) 
.04 .08 .I6 .31 .62 1.25 2.50 5 10 20 40 
Organism 
C. albicans (20) 
CF 
CF + AmB 
CF 
C F + 5 F C  
10 20 25 100 
5 10 15 100 
20 80 90 95 100 
25 50 60 70 100 
C. tropicalis (8) 
CF 
CF+AmB 
12 25 37 
12 
50 62 100 
25 50 100 
25 50 62 100 
25 50 75 100 







50 62 100 
37 100 
C. parapsilosis (8) 
CF 
CF + AmB 
CF 





Candida species (6)* 
CF 
CF+AmB I CF 17 50 100 17 50 100 17 33 100 
CF+5FC 17 50 100 
* C. krusei (2), C. pseudotropicalis (2). C. guilliermondii ( I ) ,  C. lusitaniae (1) 
tropicalis strains and 3 C. albicans strains. 
The addition of flucytosine to cilofungin 
was frequently antagonistic, as noted in 7 
C. albicans, 1 C. tropicalis, and 1 C. para- 
psilosis isolates. 
Table 4 shows MFCs for amphotericin B 
and flucytosine when used alone and when 
cilofungin was added. Addition of cilofun- 
gin to amphotericin B was synergistic for 5 
strains - 2 C. tropicalis and 3 C. glabrata. 
This same combination was antagonistic 
for 7 strains - 3 C. parapsilosis, 2 C. tropi- 
calis, and one each of C. albicans and c. 
glabrata. When cilofungin was added to 
flucytosine, synergism occurred 4 times, in 
one strain each of C. albicans, C. tropicalis, 
C. glabrata, and C. krusei. This combina- 
tion was antagonistic in 16 of the 50 strains 
(32 YO) - 6 C. parapsilosis, 4 C. glabrata, 
and one each of C. albicans, C. tropicalis, 
C. krusei, C. guilliermondii, C. pseudo- 
tropicalis, and C. lusitaniae. 
In the 12 instances of synergism noted 
when MFCs were compared for single vs. 
two drugs, 7 were only 4-fold decreases in 
the MFC. Antagonism, which occurred in 
37 of the 200 combinations tested, was at 
the 4-fold level in 18 of the 37 instances. 
Discussion 
Cilofungin is a new antifungal agent that 
has a mechanism of action different from 
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Table 4: Comparison of MFC of amphotericin B (AmB) and flucytosine (5FC) alone or with cilofungin 
(CF) against 50 strains of Cundida 
Cumulative percentage of strains at indicated concentration (pg/ml) 
.01 .02 .04 .08 .16 .31 .62 1.25 2.50 5 10 
Organism 
C. albicans (20) 
AmB 




5 60 95 100 
5 10 30 50 55 100 
10 20 30 40 45 100 
C. tropicalis (8) 
AmB 12 50 62 a7 100 
AmB + CF 50 62 75 100 
5 FC 12 25 37 1 00 
5FC+CF 12 25 37 100 
C. glabrata (8) 
AmB 25 50 87 100 
AmB + CF 37 87 100 
5 FC 25 50 62 75 100 
5FC+CF 12 37 50 62 75 100 
C. parapsilosis (8) 
AmB 
AmB + CF 
5 FC 
5FC+CF 
12 37 75 100 
12 25 50 100 
12 37 50 87 100 
12 37 50 75 87 100 
Candida species (6)* 
ArnB 17 67 83 100 
AmB + CF 33 67 100 
5 FC 17 33 50 83 100 
5FC+CF 17 50 67 83 100 
* C. krusei (2), C. pseudotropicalis (2), C. guilliermondii (l), C. lusitaniae (1) 
other antifungal agents in that it inhibits 
synthesis of beta-173-glucan leading to 
cell wall damage (3). It is possible that ci- 
lofungin might act synergistically with 
other antifungal agents, especially flucyto- 
sine, which acts, not on the cell wall, but at 
the level of DNA replication (5). Although 
it is possible to get synergistic action with 
two agents active at the level of the cell 
wall and cell membrane, such as cilofungin 
and amphotericin B, it seems less likely 
that this combination will result in synerg- 
ism. 
We found that, indeed, cilofungin added 
to amphotericin B showed only minimal 
synergistic inhibition or killing of any of 
the Cundidu species tested. When the 
corresponding studies were performed, 
which looked at the effect of sub-inhibi- 
tory concentrations of amphotericin B 
added to cilofungin, synergy did not occur 
in any strain tested. 
We also found that synergistic inhibition 
or killing of Cundidu strains was rarely 
noted with the combination of cilofungin 
and flucytosine. In fact, antagonism was 
quite common with this combination. In 
no instance did a resistant strain become 
susceptible to cilofungin or flucytosine 
when the second drug was added. 
The usefulness of cilofungin in Cundidu 
infections is not known at this time. It 
would appear to be active against C. ulbi- 
cum and C. tropicalis by in vitro tests (2, 3, 
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7). We could not verify by our in vitro as- 
says a potential role for combination ther- 
apy with amphotericin B-cilofungin or flu- 
cytosine-cilofungin. However, studies 
comparing cilofungin alone with combina- 
tion therapy in experimental Cundidu in- 
fections could possibly show an in vivo 
synergistic effect not detected by in vitro 
assays. 
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